Recent Updates
Recently added Catalysts
CRIS Neutral Sentiment

Hospital of the University of Pennsylvania

Key Takeaway: The article provides an overview of the Hospital of the University of Pennsylvania, detailing its management structure, collaborations, patient studies, and pipeline of drugs. It highlights various sponsored studies such as TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL. Additionally, it mentions the company's commitment to compassionate use policies and provides resources for investors.
Price reaction · baseline $109 (2024-10-22 close) · hit pre-market · 20 other CRIS headline(s) in the window, move may be shared
day 0 close · peak
-4.2%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~1 mo
High dilution risk
Lead asset
Emavusertib
Phase 2 · Chronic Lymphocytic Leukemia

Full Press Release Details

• About Company Overview Management Board of Directors Advisory Boards
• Collaborations Partner Collaborations Scientific & Research Collaborations
• Patients Patients Overview Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL Understanding Primary CNS Lymphoma Compassionate Use Policy
• Pipeline Pipeline Overview Emavusertib (CA-4948) Fimepinostat CA-170 CA-327
• Scientific Resources
• Investors Overview Press Releases Events and Presentations Corporate Governance Committee Composition Contact the Board Financial Information SEC Filings Annual Reports IRS Form 8937 Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage Contact Us
• Careers Life at Curis Open Positions Benefits
• Contact
• Company Overview
• Management
• Board of Directors
• Advisory Boards
• Partner Collaborations
• Scientific & Research Collaborations
• Patients Overview
• Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• Understanding Primary CNS Lymphoma
• Compassionate Use Policy
• Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• TakeAim Lymphoma
• TakeAim Leukemia
• TakeAim CLL
• Pipeline Overview
• Emavusertib (CA-4948)
• Fimepinostat
• CA-170
• CA-327
• Overview
• Press Releases
• Events and Presentations
• Corporate Governance Committee Composition Contact the Board
• Financial Information SEC Filings Annual Reports IRS Form 8937
• Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage
• Contact Us
• Committee Composition
• Contact the Board
• SEC Filings
• Annual Reports
• IRS Form 8937
• Interactive Chart
• Historical Stock Lookup
• Analyst Coverage
• Life at Curis
• Open Positions
• Benefits

Frequently Asked Questions

What studies are sponsored by the Hospital of the University of Pennsylvania?

The hospital sponsors studies such as TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL.

What is the focus of the TakeAim studies?

The TakeAim studies focus on various types of blood cancers, including lymphoma and leukemia.

What is Emavusertib?

Emavusertib (CA-4948) is one of the drugs in the hospital's pipeline.

Does the hospital have a compassionate use policy?

Yes, the hospital has a compassionate use policy for patients.

Last updated: Oct 23, 2024